New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: QuickLogic Corporation (NASDAQ:QUIK), Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX), Synthetic Biologics Inc (NYSEMKT:SYN), McEwen Mining Inc (NYSE:MUX)
QuickLogic Corporation (NASDAQ:QUIK) showed a volume of 1.49 million shares by the end of last trade whereas the average volume of the stock remained 4.90 million shares. The stock opened the session at $4.66 but then moved to $4.61. At that price, the stock showed a negative performance of -0.65%. QuickLogic Corporation develops and markets semiconductor solutions. It is a fabless semiconductor company that designs, markets and supports primarily Customer Specific Standard Products (CSSPs), and Field Programmable Gate Arrays (FPGAs), associated design software and programming hardware. The Company’s CSSPs are customized semiconductor solutions created from its solution platforms, including ArcticLink III, ArcticLink II, ArcticLink, PolarPro II, PolarPro,
Will QUIK Get Buyers Even After The Recent Rally? Find Out Here
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) opened the session at $2.10 and closed the session at $2.02. The stock showed a negative performance of -2.88% in previous trading session. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction. As of December 31, 2011, the Company was in the early stages of developing CPP-115,
Has CPRX Found The Bottom And Ready To Gain Momentum? Find Out Here
Synthetic Biologics Inc (NYSEMKT:SYN) opened the session at $1.90 and closed the session at $1.82. The stock showed a negative performance of -3.70% in previous trading session. Traded with volume of 1.49 million shares in the prior session and the average volume of the stock remained 613,843.00 shares. The beta of the stock remained 1.65. Synthetic Biologics, Inc., formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic deoxyribonucleic acid (DNA)-based therapeutics and disease-modifying medicines for serious illnesses. Its initial synthetic biologic product candidate is intended to treat pulmonary arterial hypertension (PAH) by delivering therapeutic DNA to the lungs of PAH patients and controlling long-term expression of such DNA via an oral daily pill. In addition, the Company has several small molecule clinical-stage programs. In this area the Company is developing,
Why Should Investors Buy SYN After the Recent Fall? Just Go Here and Find Out
McEwen Mining Inc (NYSE:MUX) traded with volume of 1.47 million shares in the prior session and the average volume of the stock remained 2.18 million shares. The beta of the stock remained -0.28. McEwen Mining Inc. (McEwen Mining), formerly US Gold Corporation, is engaged in the exploration for and production of precious metals in the United States, Mexico and Argentina. McEwen Mining’s operating segments include USA and Mexico. The Company holds an interest in numerous exploration and development stage properties and projects in Nevada, Mexico and Argentina, as well as a 49% equity interest in the gold-silver San Jose Mine in Santa Cruz Province, Argentina. The Company holds interests in approximately 1,631 square miles of mineral concessions in west central Mexico.
Is MUX a Solid Investment at These Levels? Read This Report For Details
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)